Human race has been persistently involved in a never ending pursuit for discovery and innovation in every field with a special inclination towards medical sciences. The perseverant efforts have triggered swift evolution in the realm of diagnostic tools and techniques. In-vitro diagnostic (IVD) tests are deployed for examining specimens including blood and tissues extracted from human body chiefly in order to detect the presence of concerning physiological/pathological state, or concerning congenital abnormality. Under the IVD market falls the ‘Molecular Diagnostics’ sector which involves performing analysis at the molecular level, and thereby measurement of DNA, RNA, proteins or metabolites to detect genotypes, mutations or biochemical changes, or to test for specific states of health or disease. Such diagnostic methods are capable of detecting viruses, bacteria, and parasites at a fast pace with greater sensitivity and specificity. The molecular diagnostics procedures for infectious diseases including HPV, CT/NG; and the deadly gene linked cancer represent the largest market category in terms of revenue generation. Since the realm of cancer detection and screening procedures is undergoing a major change, the Oncology segment of the market is poised to undergo noteworthy expansion in the near future thereby driving the molecular diagnostics market on the holistic basis. As of now, the global molecular diagnostics market is characterized by growth in large value mergers and acquisitions, personalized treatment in the field of Oncology and reimbursement trend. While the global molecular diagnostics marketplace remains marred by challenges like rising price pressures and growing regulatory hurdles; the underlying growth drivers including the ever increasing demand for better healthcare solutions, coupled with ageing world population, reimbursement, increasing insurance density, growing demand for genetic testing and rising new incidences of cancer, are taking the molecular diagnostics market to new heights. The report analyzes the global molecular diagnostics market on a global scale and its various segments and also provides detailed information regarding the key umbrella markets including the diagnostics and IVD industry. It further discusses the various industry trends, growth drivers and challenges faced by the respective industry. In addition to the market contention prevalent in the global molecular diagnostics market, major industry players including Roche Holdings, Abbott Laboratories, Hologic and Novartis AG are profiled herein.

1. Global Molecular Diagnostics Market Report
----------------------------------------------------------------
2013
View Report Details

2. Executive Summary
Human race has been persistently involved in a never ending pursuit for discovery and innovation in every field with a special inclination
towards medical sciences. The perseverant efforts have triggered swift evolution in the realm of diagnostic tools and techniques. In-vitro
diagnostic (IVD) tests are deployed for examining specimens including blood and tissues extracted from human body chiefly in order to
detect the presence of concerning physiological/pathological state, or concerning congenital abnormality. Under the IVD market falls the
„Molecular Diagnostics‟ sector which involves performing analysis at the molecular level, and thereby measurement of DNA, RNA, proteins
or metabolites to detect genotypes, mutations or biochemical changes, or to test for specific states of health or disease. Such diagnostic
methods are capable of detecting viruses, bacteria, and parasites at a fast pace with greater sensitivity and specificity.
The molecular diagnostics procedures for infectious diseases including HPV, CT/NG; and the deadly gene linked cancer represent the
largest market category in terms of revenue generation. Since the realm of cancer detection and screening procedures is undergoing a
major change, the Oncology segment of the market is poised to undergo noteworthy expansion in the near future thereby driving the
molecular diagnostics market on the holistic basis.
As of now, the global molecular diagnostics market is characterized by growth in large value mergers and acquisitions, personalized
treatment in the field of Oncology and reimbursement trend. While the global molecular diagnostics marketplace remains marred by
challenges like rising price pressures and growing regulatory hurdles; the underlying growth drivers including the ever increasing demand
for better healthcare solutions, coupled with ageing world population, reimbursement, increasing insurance density, growing demand for
genetic testing and rising new incidences of cancer, are taking the molecular diagnostics market to new heights.
The report analyzes the global molecular diagnostics market on a global scale and its various segments and also provides detailed
information regarding the key umbrella markets including the diagnostics and IVD industry. It further discusses the various industry trends,
growth drivers and challenges faced by the respective industry. In addition to the market contention prevalent in the global molecular
diagnostics market, major industry players including Roche Holdings, Abbott Laboratories, Hologic and Novartis AG are profiled herein.
By combining SPSS Inc.‟s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the
industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to
determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or
predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
View Report Details

3. In-vitro diagnostic (IVD) tests are medical tests performed in order to diagnose diseases through
chemical assays in a controlled environment outside a living organism. ..
The global diagnostics market was valued at US$........billion in
2005, which increased up to US$........ billion in the year end 2011
at the compound annual growth rate of ………..% during the cited
period.
As of 2011, the global IVD market showed an increase of
approximately ………% rising from US$........... billion in 2010 to
US$........... billion in 2011. The same registered a CAGR of
approximately ………….% for period spanning 2006 to 2011
As of 2012, the key segments of the global IVD market included
immunochemistry which constituted ………..% of the market,
while self monitoring blood glucose accounted for …………%
share. On the other hand, point of care diagnostics constituted
…………% share followed by molecular diagnostics with ……..%
share.
2006 2007 2008 2009 2010 2011
US$Billion
Global Diagnostics Market (2005-2012E)
Global IVD Market (2006-2011)
2005
2006
2007
2008
2009
2010
2011
2012E
US$ Billion
Immunochemistry Self Monitoring Blood Glucose
Point of Care Diagnostics Molecular Diagnostics
Tissue Diagnostics Hematology
Microbiology Hemostasis
IVD Market Share by Major Segments (2012)

4. Molecular diagnostics (MDx) involve performing analysis at the molecular level, and thereby measurement
of DNA, RNA, proteins or metabolites to detect genotypes, mutations or biochemical changes, or to test
for specific states of health or disease. ..
The global molecular diagnostics market was worth US$...... billion in
2005, which has recorded a CAGR of ……….% reaching US$..... billion
in 2012. The market recorded a Y-O-Y growth of ……..% in 2012.
Infectious disease testing accounted for ……% of the molecular
diagnostic market, while oncology market constituted nearly ….% and
genetics & prenatal claimed the remaining ………% of the respective
market.
In 2007, the market for genetic testing was valued at US$...... billion and
it registered a CAGR of ………% to reach US$......... billion in 2011.
Currently, genetic testing is being acknowledged as a highly attractive
segment in the molecular diagnostics market. Many factors like direct to
consumer genetic testing, and growing awareness regarding the positive
aspects of genetic testing are driving the market.
Global Genetic Testing Market (2007-2011)Molecular Diagnostics Market Share by Segment
)
Global Molecular Diagnostics Market (2005-2012)
Infectious disease Genetic & Prenatal Oncology
2005 2006 2007 2008 2009 2010 2011 2012
US$Billion
2007 2008 2009 2010 2011
US$Billion

5. In molecular diagnostics industry, the growth is driven primarily by population demographics and
advancements made in medical knowledge and technology
The global IVD market is highly consolidated with the 5 key players controlling more than 60% of the global operations. In 2012, the
key players including Roche, Siemens, Abbott, Johnson and Johnson, and Danaher constituted …….% of the global IVD market
Abbott and Novartis held …….% share each in the molecular diagnostic market, which puts them in a No. 2 position, but
considerably behind market leader Roche which accounts for ……….% share.
Taking into account the numerous factors and growth drivers affecting the growth of global molecular diagnostics market, for the
year 2013, the market opportunity of the same is anticipated to be US$..........billion, estimated to increase by ……% as compared to
the US$.........billion that existed in 2012. The global molecular diagnostics market is likely to grow from US$.............. billion in 2012
to US$...... billion in 2015, at a CAGR of ………..%. The strong future projection for the growth in the molecular diagnostics market is
mainly on the back of rising incidences of cancer. The market is expected to be driven by a number of factors, such as rising
awareness among the people with respect to better healthcare options, and development of various advanced treatment solutions
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
2010
2011
2012
2013F
2014F
2015F
US$ Billion
Roche Abbott Novartis
Hologic Qiagen Becton Dickinson
Cepheid Siemens Others
Global Molecular Diagnostics Market Forecast (2010-2015F)Global Molecular Diagnostics Market Share by Company (2012)

6. Table of Contents
1. Diagnostics: An Overview
1.1 In Vitro Diagnostics
1.2 Molecular Diagnostics
2. Diagnostics Market Structure
2.1 In Vitro Diagnostics (IVD) Market
-Market Value
-Market Segments
2.2 Global Molecular Diagnostics Market
-Market Value
-Market Segments
2.2.1 Molecular Diagnostics - Segment Analysis
a) HPV
-Market Value
-Penetration Rate
b) CT/NG
-Market Value
2.2.2 Global Genetic Testing Market
-Market Value
3. Market Dynamics
3.1 Industry Trends and Developments
3.1.1 Molecular Diagnostics in Oncology: Focus on
Personalized Treatment
3.1.2 Growing M&A Activity in the Molecular
Diagnostics Landscape
3.1.3 Reimbursement
3.1.4 Penetrating Point of Care Diagnostics
3.1.5 Emerging Korean Molecular Diagnostics
Business
List of Charts & Tables
List of Charts
IVD Market – Segments by Technology
Molecular Diagnostcs – Traditional Process
Main Purposes of Molecular Diagnostics
Global Diagnostics Market (2005-2012E)
Global IVD Market (2006-2011)
IVD Market Share by Major Segments (2012)
Global Molecular Diagnostics Market (2005-2012)
Molecular Diagnostics Market Share by Segment
Infectious Disease Market Segmentation
HPV Testing Market Penetration Rates in the US (2010-2013E)
Global Genetic Testing Market (2007-2011)
Current Standards of Care in Various Therapeutic Areas (2011)
Number of IVD M&A‟s per Year (2009-2012)
Number of M&A Deals According to Primary IVD Target Company Focus
(2009-2012)
Number of IVD Partnership Deals by Deal Type
Number of Cancer Cases Worldwide (2007-2011)
World Population with Diabetes, Age Group 20-79 years (2006-2012)
Global Ageing Population (2005-2013F)
Global GDP (2001-2011)
World GDP per Capita (2005-2011)
Global Insurance Density (2004-2011)
Global Vitamin D Market (2007-2011)
Vitamin D Tests Penetration by Region (2011E)
Number of Genetic Tests and Laboratories Available Worldwide (1993-2011)
Worldwide Number of Diseases with Availability of Genetic Testing (2005-
2011)
Global IVD Market Share by Company (2012)
Global Molecular Diagnostics Market Share by Company (2012)
Global CT/GC Market Share by Leading Companies (2011)
Hologic‟s Revenue Share by Business Segment (2012)
Hologic‟s Revenues and Net Income (2008-2012)
Abbott Laboratories Revenue – Share by Segments (2012)
Abbott Laboratories Revenue (2008-2012)

7. 3.2 Growth Drivers
3.2.1 Increasing Prevalence of Cancer
3.2.2 Rising Demand for Better Healthcare Options
3.2.3 Diabetic Population
3.2.4 Growing Ageing Population (+60 Years)
3.2.5 Ameliorating Economic Conditions
3.2.6 Increasing Insurance Density
3.2.7 Low Penetration of Vitamin D Tests
3.2.8 Growth in Genetic Testing Procedures
3.3 Challenges
3.3.1 Stringent Regulations
3.3.2 Mounting Price Pressure
4. Competitive Landscape
-Competitive Overview
-Market Share
5. Company Profiles
5.1 Hologic, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Focus on Research & Development
-Expansion via Strategic Acquisitions
5.2 Abbott Laboratories
5.2.1 Business Overview
5.2.2 Financial Highlights
5.2.3 Business Strategies
-Mergers and Acquisitions
-Expansion in Emerging Markets
5.3 Roche Holdings AG
5.3.1 Business Overview
5.3.2 Financial Overview
List of Charts
Roche‟s Revenues by Business Segments (2012)
Roche‟s Revenues and Net Income (2008-2012)
Novartis‟ Revenue Share by Business Segments (2012)
Novartis‟ Revenues and Net Income (2008-2012)
Global Molecular Diagnostics Market Forecast (2010-2015F)
List of Tables
Global HPV Market Model (2011-2015E)
CT/NG Market Model (2011-2015E)
Main M&A Deals in the Molecular Diagnostics Sector (2009-2012)
Patients Worldwide Waiting for Better Treatment Options (2011)
IVD Market Key Players-by Segments
Dependent & Independent Variables (2007-2012)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

8. 5.3.3 Business Strategies
-Focus on Innovative Diagnostics
-Expertise in Molecular Biology
5.4 Novartis AG
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
-Strong Product Pipeline
-Leadership in Innovation
6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

9. Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
Vikas Gupta
BD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “Global Molecular Diagnostics Market”.
To know more about this report or for any customized research requirement, please contact the following:
View Report Details